Last edition
News about "Activated PI3K Delta Syndrome"
Pharming Launches Joenja in Japan for APDS Patients Aged 4 Years and Older
Pharming has launched Joenja (leniolisib) in Japan for adults and children aged 4 years and older with APDS, marking its first commercial availability for children aged 4 to 11 years.
Activated PI3K Delta Syndrome | 13/08/2026 | By News Bureau
Pharming Secures EU Approval for Joenja as First Targeted Treatment for Rare Immune Disorder APDS
Pharming Group has received European Commission approval for Joenja, expanding treatment access for patients with activated PI3K delta syndrome and strengthening therapeutic options for rare immune disorders.
Activated PI3K Delta Syndrome | 26/05/2026 | By News Bureau | 104
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy